Vol. 12, Issue 1 (2023)

Author(s):
Suryakant Ranjan, Himanshu Sekhar Behera, Arun Kumar S, Bitish Kumar Nayak, Dr. Bijay Kumar Pany, Dr. Gour Hari Santra, Dr. Awaneet Kumar, Suchismita Mohapatra, Kawaljeet Kaur and Himanshu Jangid

Abstract:
There is a desperate requirement to identify non-invasive biomarkers which conceivably could delay development of the Alzheimer’s disease. Biomarkers are a quantifiable signal of a certain biological condition. Biomarkers for Alzheimer can be recognized using Blood, Cerebrospinal fluid, Saliva, Urine sample has been an aim of numerous experimenter for several years. Aβ40, Aβ42, total tau, and p-tau in different body samples have characteristic use in AD. Assessment of CSF biomarker is helpful in the forecast the risk of progression from mild cognitive impairment to AD. This study is an outline of in progress joint efforts to set up biomarkers as a characteristic tool and carry out them in diagnostic procedures of the above-mentioned disease.